

Resource Summary Report

Generated by ASWG on Aug 9, 2026

PE anti-human CD4

RRID:AB_2562053

Type: Antibody

Proper Citation

BioLegend Cat# 300539, RRID:AB_2562053

Antibody Information

URL: http://antibodyregistry.org/AB_2562053

Proper Citation: BioLegend Cat# 300539, RRID:AB_2562053

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD4

Description: This monoclonal targets CD4

Target Organism: human

Clone ID: Clone RPA-T4

Antibody ID: AB_2562053

Vendor: BioLegend

Catalog Number: 300539

Alternative Catalog Numbers: 300508, 300507, 300550

Record Creation Time: 20250819T234559+0000

Record Last Update: 20250820T062105+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD4.

No alerts have been found for PE anti-human CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Chantzoura E, et al. (2026) The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity. Cancer immunology research, 14(2), 243.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. Cell reports, 43(12), 115015.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. Cell reports. Medicine, 5(5), 101526.

Vanoni G, et al. (2021) Human primed ILCPs support endothelial activation through NF- κ B signaling. eLife, 10.

Bergamaschi L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity, 54(6), 1257.